FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC By Ogkologos - August 5, 2026 70 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... July 28, 2025 Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole... September 24, 2021 Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... April 6, 2022 ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report... September 18, 2026 Load more HOT NEWS Beloved Preschool Teacher Dies of Breast Cancer, Leaving Behind 9-Year-Old Son Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... How targeted screening can help the NHS save lives from lung... FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative...
